Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5246757 | 1.00 | CNR1 (0.39) | CNR1CNR2KDM1AF2RL1OPRM1 | |
| SCHEMBL5246764 | 1.00 | CNR1 (0.39) | CNR1CNR2KDM1AF2RL1OPRM1 | |
| SCHEMBL4479936 | 0.90 | LMNA (0.42) | NPC1MEN1KMT2AGAA | |
| SCHEMBL16490799 | 0.89 | MEN1 (0.47) | GRM5GRM1MEN1KMT2AGAA | |
| SCHEMBL2350223 | 0.83 | ADORA1 (0.42) | GRM5 | |
| SCHEMBL5230371 | 0.81 | GPR119 (0.38) | — | |
| SCHEMBL6414267 | 0.80 | CYP11B2 (0.36) | KDM1ARORCKMT2A | |
| SCHEMBL4763188 | 0.80 | ALDH1A1 (0.43) | GRM5GRM1 | |
| SCHEMBL5230008 | 0.79 | STS (0.43) | PKM | |
| SCHEMBL5230017 | 0.79 | STS (0.43) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0869968-B1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1000085-B1 | TREATMENT OF INSULIN RESISTANCE WITH GROWTH HORMONE SECRETAGOGUES | PFIZER PROD INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6867202-B1 | Increasing level of endogenous growth hormone using growth hormone secretagogue such as 2-amino-N-(2-(3a-benzyl-2-methy-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-(4,3 -c)pyridin-5-yl)-1-benzyloxymethyl-2-oxo-ethyl)-isobutyramide tartarate salt | PFIZER INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-6630487-B2 | Treatment of insulin resistance with growth hormone secretagogues | PFIZER INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030100561-A1 | Administering 2-amino-N-(1-(3a-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridine-5-carbonyl)-4-phenyl-butyl) -isobutyramide for treating congestive heart failure, obesity | CARPINO PHILIP ALBERT (US) | 2003-05-29 | — | — | US | disclosed |
| US-6482825-B2 | HEXAHYDRO-PYRAZOLO-(4,3-C)PYRIDINE DERIVATIVES USEFUL FOR INCREASING THE ENDOGENOUS PRODUCTION OR RELEASE OF GROWTH HORMONE IN A HUMAN OR OTHER ANIMAL, THUS TREAT OR PREVENT OSTEOPOROSIS | PFIZER INC. | 2002-11-19 | — | — | US | disclosed |
| US-6448263-B1 | SYNTHESIS ROUTES FOR SUCH AS 2-AMINO-N-(2-(3A-(R)-BENZYL-2-METHYL-3-OXO-2,3,3A,4,6,7-HEXAHYDRO-PYRAZOLO -(4,3-C) PYRIDIN-5-YL)-1-(R)-BENZYLOXYMETHYL-2-OXO-ETHYL)-ISOBUTYRAMIDE L-TARTARIC ACID SALT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020049196-A1 | Growth-hormone secretagogues | RAQUALIA PHARMA INC. (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6306875-B1 | ADMINISTERING GROWTH HORMONES DIPEPTIDE COMPOUNDS WHICH ARE GROWTH HORMONE SECRETAGOGUES AND ARE USEFUL FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS. | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6278000-B1 | INCREASE LEVEL OF ENDOGENOUS GROWTH HORMONE; USEFUL IN THERAPY AND PROPHYLAXIS OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING AND OBESITY, ACCELERATING BONE FRACTURE REPAIR | PFIZER INC. | 2001-08-21 | — | — | US | disclosed |
| US-6124264-A | GROWTH HORMONE SECRETAGOGUE IN A HUMAN OR OTHER ANIMAL TO TREAT OSTEOPOROSIS, CONGESTIVE HEART FAILURE, AGING, OBESITY; BONE AND WOUND HEALING AGENTS | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6110932-A | INCREASE THE LEVEL OF ENDOGENOUS GROWTH HORMONE FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ACCELERATING WOUND HEALING | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6107306-A | OSTEOPOROSIS | PFIZER INC. (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100561-A1 | Administering 2-amino-N-(1-(3a-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridine-5-carbonyl)-4-phenyl-butyl) -isobutyramide for treating congestive heart failure, obesity | GIPR, GHSR, GPR119 | CNR1 366/4885CNR2 288/4885KDM1A 1976/4885 |
| US-20020049196-A1 | Growth-hormone secretagogues | GHSR, GHRHR, IGFBP6 | CNR1 1739/4885CNR2 1744/4885KDM1A 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.